Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
about
Management of Ewing sarcoma family of tumors: Current scenario and unmet needDiagnosis and treatment of Ewing sarcoma of the bone: a review articleBone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma.Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors.Treatment pathway of bone sarcoma in children, adolescents, and young adultsA study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.Current therapeutic approaches in metastatic and recurrent ewing sarcomaCamptothecin-based regimens for treatment of ewing sarcoma: past studies and future directionsMetastatic Ewing's sarcoma/PNET of kidney in 40 year old patientMolecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours.Endoplasmic reticulum targeting in Ewing's sarcoma by the alkylphospholipid analog edelfosineTargeted therapy in Ewing sarcoma.Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus.Advances in paediatric cancer treatmentEWING'S SARCOMA: EPIDEMIOLOGY AND PROGNOSIS FOR PATIENTS TREATED AT THE PEDIATRIC ONCOLOGY INSTITUTE, IOP-GRAACC-UNIFESPPilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology GroupA phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-upAn Unusual Location of Extraosseous Ewing's Sarcoma.Expanded Access Through Cancer Trials Support Unit to Children's Oncology Group Sarcoma Trial AEWS1031 for Adolescents and Young AdultsPharmacotherapy of sarcoma.Sarcomas gone bad: what to do about recurrent Ewing sarcoma.Ewing sarcoma: clinical state-of-the-art.Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.Experimental research on the in vitro antitumor effects of Crataegus sanguinea.Topotecan and cyclophosphamide in adults with relapsed sarcoma.Intracardiac Low-grade Sarcoma Following Treatment for Ewing Sarcoma.Managing sarcoma: where have we come from and where are we going?The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma.Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.Prognostic factors and clinical outcome of patients with Ewing's sarcoma family of tumors in adults: multicentric study of the Anatolian Society of Medical Oncology.Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing's Sarcoma: A Systematic Review.Role of High-dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Ewing's Sarcoma: A Case Report with Focused Review of Literature.Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducersEtoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: A large retrospective studyBone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P2860
Q28073218-1CD2589D-237A-45AE-8428-E40CB6678AC4Q28085071-7C09B595-6E86-497F-AA86-436BAB4A3EEAQ33274572-05759105-97E6-4857-95E6-180213989C44Q33404428-7A2C9433-481E-4F5E-A0B5-F4A56512789EQ33618884-98B2D2C5-AF1F-435F-808B-E7087E791BF1Q33835657-A56C405C-04A1-4E4F-8621-D873363B8EE3Q34136875-37130722-0E9A-47EF-A231-69456BAB5E85Q34373180-03170A72-A320-4715-A4D0-A73654366B0BQ34787772-D7967C9F-5DCC-40C5-A5CD-F6A63273304BQ35884342-7AD5BD88-EB4E-4516-BD46-EC0BE4C6C2EBQ35957998-1ADA60EA-6DD4-4A39-AD5F-696204DB0FA6Q35987417-E29BCCCE-ED0F-46CD-9254-8BE51896E21BQ36011879-DFE7D796-39F7-4F5E-9615-745057539FEFQ36191321-A46D08FE-9BD1-4F68-8AC8-5CB5B11D4C42Q36508630-5305B2BB-1B1B-4B68-8B89-94608DFB0B44Q36705188-CF3164F6-4DE3-4476-AFC6-91DCBCF2241AQ36881113-63A5A7BC-C86B-40C4-A667-F5C0B4D74FA0Q36970948-0CC2CF77-34E2-494A-B510-481F206E77D1Q37049291-7D5DDB16-6B1A-41DA-B95C-7BD9C966225AQ37158211-F25DEF00-5E7C-494A-8D87-7C5C028A7F2AQ37532566-73287024-BB88-4B6D-B732-A3088FBD46E9Q37890995-0263BF53-8100-4DEE-871F-D3BCB9DC165FQ37980482-74F818E0-DAF7-4B3B-9BF5-264D2E080564Q38113988-D187471B-78FB-4A5F-BE36-F9D8DDD2E1DBQ39191728-80B0EACB-3822-49BF-9835-457C3CDA3AAAQ40278945-B5CB70CA-5A6F-42F8-A89A-9E5A940832A2Q40433321-3FDEF3E3-4A07-4133-A0CD-985C111DB866Q41988197-D676D12C-BC63-440D-9D88-9A95AD6BB5FDQ43833260-1E7F22EE-F015-4D8A-B238-028FA6728B8FQ44611540-26884E8A-2D8D-40B6-B2E4-C4D5FAE3C6AEQ45969231-5AE9D1E8-3A3C-47C3-97BC-3DC91197E4CCQ55426535-A304893B-0549-4BD6-AB61-0AF56A1CBA6AQ55508881-4D55712D-05F2-42CE-876F-94A70F8235DFQ57174958-86C51EAF-AD55-4B00-A6CD-01ED69E0FF5BQ57570538-66139B9E-E6B6-4DAC-B52E-84FDFC0E3CBBQ57570627-7334549B-4210-408D-8749-318B0C8CA693
P2860
Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
@en
Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
@nl
type
label
Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
@en
Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
@nl
prefLabel
Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
@en
Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
@nl
P2093
P356
P1476
Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors
@en
P2093
Andrea Hunold
Caren Liebscher
Herbert Jürgens
Michael Paulussen
Nicole Weddeling
P304
P356
10.1002/PBC.20719
P577
2006-11-01T00:00:00Z